• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA approves AMI's Gastromark agent

Article

The Food and Drug Administration has approved a new drug applicationfor Gastromark, a gastrointestinal MRI contrast agent developedby Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagneticoral contrast agent that has been licensed to

The Food and Drug Administration has approved a new drug application

for Gastromark, a gastrointestinal MRI contrast agent developed

by Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagnetic

oral contrast agent that has been licensed to Mallinckrodt Medical

of St. Louis. The agent is marketed in Western Europe by Guerbet

under the trade name Lumirem. Gastromark will be priced at about

$25 per 300 mL, according to Jerome Goldstein, president and CEO

of Advanced Magnetics. Either 600 or 900 mL will likely be administered,

bringing the total cost to between $50 and $75 per patient.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.